318 related articles for article (PubMed ID: 10553698)
1. Mode of action of fluoroquinolones.
Hooper DC
Drugs; 1999; 58 Suppl 2():6-10. PubMed ID: 10553698
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action and resistance of older and newer fluoroquinolones.
Hooper DC
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
[TBL] [Abstract][Full Text] [Related]
3. Quinolone mode of action.
Hooper DC
Drugs; 1995; 49 Suppl 2():10-5. PubMed ID: 8549276
[TBL] [Abstract][Full Text] [Related]
4. DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica K; Zhao X
Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
[TBL] [Abstract][Full Text] [Related]
5. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
6. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of antimicrobials: focus on fluoroquinolones.
Hooper DC
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S9-S15. PubMed ID: 11249823
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
9. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.
Heddle JG; Barnard FM; Wentzell LM; Maxwell A
Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1249-64. PubMed ID: 11097055
[TBL] [Abstract][Full Text] [Related]
10. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
Hooper DC
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
Wu P; Lawrence LE; Denbleyker KL; Barrett JF
Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
[TBL] [Abstract][Full Text] [Related]
12. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
Zhao X; Xu C; Domagala J; Drlica K
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones: structure and target sites.
Higgins PG; Fluit AC; Schmitz FJ
Curr Drug Targets; 2003 Feb; 4(2):181-90. PubMed ID: 12558069
[TBL] [Abstract][Full Text] [Related]
15. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
16. DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex.
Hiasa H; Shea ME
J Biol Chem; 2000 Nov; 275(44):34780-6. PubMed ID: 11053451
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of the new quinolones: new data.
Hooper DC; Wolfson JS
Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of and resistance to quinolones.
Bearden DT; Danziger LH
Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
[TBL] [Abstract][Full Text] [Related]
19. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
20. Quinolone mode of action--new aspects.
Hooper DC
Drugs; 1993; 45 Suppl 3():8-14. PubMed ID: 7689456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
